GH Research PLC (GHRS)vsVertex Pharmaceuticals Inc (VRTX)
GHRS
GH Research PLC
$26.17
-7.83%
HEALTHCARE · Cap: $1.95B
VRTX
Vertex Pharmaceuticals Inc
$529.59
+0.29%
HEALTHCARE · Cap: $124.70B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
GHRS
Avoid23
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GHRS.
Margin of Safety
+44.2%
Fair Value
$946.78
Current Price
$529.59
$417.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GHRS
The strongest argument for GHRS centers on Debt/Equity, Altman Z-Score.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : GHRS
The primary concerns for GHRS are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
GHRS profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
GHRS carries more volatility with a beta of 1.31 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 23/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GH Research PLC
HEALTHCARE · BIOTECHNOLOGY · USA
GH Research PLC is a clinical-stage biopharmaceutical company specializing in the development of psilocybin-based therapies targeted at psychiatric and neurodegenerative disorders. With a strong pipeline designed to meet significant unmet needs in mental health treatment, the company is led by an experienced team dedicated to advancing innovative therapeutic solutions. By leveraging its unique scientific approach, GH Research aims to transform treatment paradigms and improve patient outcomes, positioning itself as a potential leader in the burgeoning mental health therapeutics market.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?